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Victor W. Weedn, M.D. ****
William J. Winslade, Ph.D. *****
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I. INTRODUCTION
Informed consent in general and the disclosure of treatment options by
physicians in particular have received little attention in clinical medical liter-
ature despite the increasing legal emphasis on these issues.' Patients in the
* Presented in part at the 49th Annual Meeting of the American Academy of
Dermatology, Atlanta, Georgia, December 1990. The material presented is intended as a
general presentation of medicolegal issues of interest to dermatologists in the United States.
Specific legal advice should be sought with a licensed attorney in your jurisdiction. The
opinions or assertions herein are those of the authors and do not necessarily reflect the view of
the Department of Army or the Department of Defense.
** Department of Dermatology, The University of Texas Medical Branch at Galveston,
Texas.
*** Department of Dermatology, The University of Texas Medical Branch at Galveston,
Texas.
**** The Office of the Armed Forces Medical Examiner, The Armed Forces Institute of
Pathology, Washington, D.C.
***** Institute for the Medical Humanities, The University of Texas Medical Branch at
Galveston, Texas.
****** B.A., Georgetown University; J.D., The Catholic University of America, The Colum-
bus School of Law.
1. In 1982, the President's Commission for the Study of Ethical Problems in Medicine
and Biomedical and Behavioral Research sought to document emerging legal and medical
trends which relate to informed consent. In discussing the tension between "medical paternal-
ism" and "patient sovereignty," the Commission noted that "[both positions attempt to vest
exclusive moral agency, ethical wisdom, and decisionmaking authority on one side of the rela-
tionship, while assigning the other side a dependent role." 1 PRESIDENT'S COMM'N FOR THE
STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIOMEDICAL AND BEHAVIORAL RE-
SEARCH, MAKING HEALTH CARE DECISIONS: A REPORT ON THE ETHICAL AND LEGAL IM-
PLICATIONS OF INFORMED CONSENT IN THE PATIENT-PRACTITIONER RELATIONSHIP 36
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United States are demanding more information about their diagnoses and
treatment options before physicians begin case management.2 Implicit in the
encounters between physician and patient lies a mixture of different commu-
nication styles and expectations for participation in the therapeutic relation-
ship.3 It has been suggested that physicians refuse to share information in
order to maintain power over their patients.4 However, this Article pro-
poses that the maximum exchange of information enhances patient auton-
omy and facilitates the therapeutic process.5
Disclosure of relevant diagnostic facts and treatment options is essential to
the informed consent process by which the physician and patient both arrive
at medical management decisions. Yet, the practice of informed consent is
compromised if reasonable diagnostic or treatment options are withheld by
the physician.6 This survey was designed to document the extent to which
disclosure practices within the specialty of dermatology meet the ideal of
shared decision-making." Following a brief summary of the methods used
and results obtained, the evaluation of informed consent is divided into two
(1982) [hereinafter PRESIDENT'S COMM'N]. For an early effort to survey informed consent
among physicians' practices in the United States, see Louis Harris & Assocs., Views of In-
formed Consent and Decisionmaking: Parallel Surveys of Physicians and the Public, in 2 PRESI-
DENT'S COMM'N FOR THE STUDY OF ETHICAL PROBLEMS IN MEDICINE AND BIOMEDICAL
AND BEHAVIORAL RESEARCH, MAKING HEALTH CARE DECISIONS: A REPORT ON THE ETH-
ICAL AND LEGAL IMPLICATIONS OF INFORMED CONSENT IN THE PATIENT-PRACTITIONER
RELATIONSHIP 17 (1982).
2. A continually developing consumerism in health care has been linked to the impor-
tant, yet poorly advocated, value of patient autonomy. See Patrick A. Malone, Granting In-
formed Consent: How Patients Can Protect Themselves, WASH. POST, July 10, 1990, Health
Magazine, at 11. In fact, it has been suggested that there exists a "bill of rights" for patients in
dealing with physicians. See Morton Hunt, Patients'Rights, N.Y. TIMES, Mar. 5, 1989, Maga-
zine, at 55. Because of this increased interest in patient autonomy, physicians have been more
responsive to disclosing potential risks associated with treatment. In the 1960s, only 1 out of
10 doctors would tell patients they had cancer; by the late 1970s, 97% of the doctors surveyed
preferred to disclose cancer diagnoses. Miriam Shuchman & Michael S. Wilkes, Asking--and
Telling, N.Y. TIMES, Feb. 12, 1989, Magazine, at 45.
3. See Ronald Schouten, Informed Consent: Resistance and Reappraisal, 17 CRITICAL
CARE MED. 1359, 1359-60 (1989).
4. Howard Waitzkin & John D. Stoeckle, The Communication of Information about Ill-
ness, reprinted in ETHICS IN MEDICINE: HISTORICAL PERSPECTIVES AND CONTEMPORARY
CONCERNS 232, 233 (Stanley J. Reiser et al. eds., 1977).
5. For a supporting view, see Midwest Medical Insurance Co, Informed Consent: Open-
ing the Doors to Physician-Patient Communication, 73 MINN. MED. 35, 36 (1990).
6. It is here that many commentators draw the nexus between a valid informed consent
and the disclosure of a requisite quantum of information. For example, informed consent is
interpreted as "a law of disclosure based on a general obligation to exercise reasonable care by
giving information." TOM L. BEAUCHAMP & JAMES F. CHILDRESS, PRINCIPLES OF BIOMEDI-
CAL ETHICS 86 (3d ed. 1989).7. Rather than abrogating patient autonomy in favor of professional control, a "'par-
ticipatory' model.., rests on the belief that both the professional and his client benefit from a
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sections. First, various legal doctrines are examined in tracing the develop-
ment of the requirements of disclosure. Second, the results of the survey are
analyzed, with particular attention to those areas in which there was a lack
of consensus in disclosure. By discussing informed consent with the goal of
meeting patients' expectations for information, this study attempts to bridge
the gap between the theory and practice of informed consent.
II. METHODS
One hundred dermatologists were surveyed at random from the 1989-
1990 Directory of the American Academy of Dermatology. 9 Only those cat-
egorized as fellows practicing within the United States were included. The
selection was based on random numbers generated by the Hewlett Packard
11 C calculator. One dermatologist was selected at random from each page
of the ninety-five page directory, and five additional dermatologists were se-
lected at random from five more randomly selected pages.
The questionnaire used in the survey described clinical case presentations
and called for the respondents to select any of the diagnostic and treatment
options for each case presentation from a listing of options that they would
disclose to a patient. Cases included the dysplastic nevus syndrome, recur-
rent basal cell carcinoma, malignant melanoma, and neonatal port-wine
stain. Respondents were encouraged to suggest alternative diagnostic or
treatment options that were not offered on the list by filling in the blank
spaces provided.
III. RESULTS
Forty-eight percent of dermatologists representing twenty-five states re-
sponded to the survey. All the dermatologists practiced in cities with popu-
lations greater than 10,000 people and 44% were in a city with a population
greater than 500,000. Seventy-five percent of the physicians were in the
thirty to forty-nine-year-old range. The responding physicians completed
their dermatology residencies between 1956 and 1988. The most common
type of practice was a solo private practice (48%), with 33% in a group
practice and 17% in an academic practice.
Seventy-seven percent of the respondents were situated less than ten miles
sharing of control over many of the decisions arising out of the relationship." Leonard L.
Riskin, Informed Consent: Looking for the Action, 1975 U. ILL. L. FORUM 580, 580.
8. JAY KATZ, THE SILENT WORLD OF DOCTOR AND PATIENT 166 (1984).
9. American Academy of Dermatology, 1567 Maple Ave., P.O. Box 3116, Evanston, Ill.
60204-3116, (708) 869-3954.
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from a Mohs micrographic surgeon,' 0 and ninety percent were located less
than fifty miles away. Thirty-eight percent of the respondents were less than
ten miles away from a pigmented lesion clinic;" forty-eight percent were less
than fifty miles away; and twenty-five percent were over two hundred miles
away. Forty-four percent of respondents were less than ten miles away from
the nearest pulsed dye laser, 2 fifty-eight percent were less than fifty miles
away, and fifteen percent were more than two hundred miles away.
The four case presentations and the survey responses are presented in Ta-
bles 1- 4. The mean number of options disclosed for each case presentation is
presented in Figure 1. No correlation patterns were found between the dem-
ographic data and responses to the case presentations.
IV. DISCUSSION
This study revealed startling differences in disclosure practices of the sur-
veyed dermatologists. Despite the degree of consensus about disclosure of
some treatment options, those instances of nondisclosure have important
ramifications for the process of informed consent in the practice of dermatol-
ogy.13 This analysis will be divided into three sections. First, a review of the
traditional standards for medical disclosure reveals that progress in advanc-
10. In 1988, The American College of Mohs Micrographic Surgery and Cutaneous Oncol-
ogy approved 21 fellowships of I year duration in Mohs micrographic surgery. Willis J. Cottel
et al., Essentials ofMohs Micrographic Surgery, 14 J. DERMATOLOGIC SURGERY & ONCOLOGY
11, 12 (1988). This training program focuses on mastering the techniques of skin cancer exci-
sion, color coding, and the freezing of tissue samples. Id. at 11. Accurate microscopic evalua-
tion of frozen tissue samples is essential in determining whether tumor removal is successful
and a "well-trained Mohs micrographic surgeon.., is often required to interpret over 100...
specimens daily. Id. at 12.
11. Of the many pigmented lesions that are diagnosed and treated at one of these facilities,
malignant melanoma and dysplastic nevus syndrome are the most important. For a discussion
of the experience with pigmented lesions at Massachusetts General Hospital see Raymond L.
Barnhill et al., Frequency of Dysplastic Nevi Among Nevomalenocytic Lesions Submitted for
Histopathologic Examination, 126 ARCHIvES DERMATOLOGY 463 (1990) (reporting the in-
creased diagnosis of dysplastic nevi over a 37-year interval).
12. Currently, the pulsed dye laser is very expensive to purchase and maintain, and few
sole practitioners and university medical centers are able to provide this service. For a brief
survey of various surgical techniques, including the pulsed-eye laser, see Christopher B.
Zachary, Surgical Therapy, in PRINCIPLES AND PRACTICE OF DERMATOLOGY 63 (W. M.
Sams, Jr. & Peter J. Lynch eds., 1990).
13. Only if a doctor is willing to provide information concerning treatment options, in-
cluding the risks associated with each, can the patient make an autonomous treatment choice.
See Joyce C. Billue, Who Owns the Patient?, 18 HEART & LUNG 530 (1989). See also David L.
Cohen et al., A National Survey Concerning the Ethical Aspects of Informed Consent and Role
of Medical Students, 63 J. MED. EDuc. 821, 828 (1988) (proposing that deficiencies in in-
formed consent may be traced to the medical education process).
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ing physician responsibility for informed consent has been very limited.14
Second, two categories of disclosure are proposed to be integrated into phy-
sician practice on a uniform basis. While treatment practices differ 5 within
the profession of dermatology, the data collected below can provide profes-
sionals with a baseline for future comparison and promote greater awareness
of emerging therapies.
A. Current Disclosure Standards
Commenting on the international differences in informed consent, the Sec-
retary of the British Medical Association stated that a patient in America
"must be informed of every possible adverse consequence of submitting to
treatment, whereas under English law the patient needs to be told about only
such risks as a responsible body of medical opinion would consider rele-
vant." 16 However, this evaluation oversimplifies the current state of the law
in this country and reflects a widespread view that informed consent is an
unfortunate appendage of defensive medicine. 7 Rather, the doctrine serves
as a vehicle for both the mutual exchange of information and a recognition
14. The early development of informed consent focused on the physician's duty to dis-
close the attendant risks of a specific procedure once it had been selected for the patient. In
referring to this practice, the California Court of Appeal stated, "A physician violates his duty
to his patient and subjects himself to liability if he withholds any facts which are necessary to
form the basis of an intelligent consent by the patient to the proposed treatment." Salgo v.
Leland Stanford Jr. Univ. Bd. of Trustees, 317 P.2d 170, 181 (Cal. Dist. Ct. App. 1957) (em-
phasis added).
15. Unfortunately, most practice-specific studies of informed consent are composed from
the perspective of defensive medicine, rather than with an eye toward clinical study. See, e.g.,
William H. Dornette, Informed Consent and Anesthesia, 53 ANESTHESIA & ANALGESIA...
CURRENT RESEARCHES 832 (1974); Alan R. Gold, Failure to Warn, 57 J. AM. OPTOMETRIC
ASS'N 317 (1986); Richard S. Goodman, Legal Liability and Orthopedic Surgery: Informed
Consent, 7 ORTHOPEDICS 1764 (1984); Donald E. Machen, Legal Aspects of Orthodontic Prac-
tice: Risk Management Concepts, 96 AM. J. ORTHODONTICS & DENTOFACIAL ORTHOPEDICS
88 (1989); Peter A. Plumeri, The Gastroenterologist and the Doctrine of Informed Consent, 5 J.
CLINICAL GASTROENTEROLOGY 185 (1983); David Poswillo, Obtaining Consent to Oral and
Maxillofacial Surgery, 18 ANNALS ACAD. MED., SINGAPORE 616 (1989); Thomas J. Smith,
Informed Consent Doctrine in Dental Practice: A Current Case Review, 1 J.L. & ETHICS DEN-
TISTRY 159 (1988).
16. John D. Havard, Green College Lectures: The Responsibility of the Doctor, 299 BRIT.
MED. J. 503, 503 (1989). See also Christopher Heneghan, Consent to Medical Treatment, 337
LANCET 421 (1991) (proposing that informed consent has not become part of British law and
disclosure remains a "professional decision"). But cf Consent Forms Issued: Is Department
Catching Up?, 62 BULL. MED. ETHICS 5 (1990) (announcing promulgation of guidelines by the
U.K. Department of Health for patient consent to examination or treatment).
17. In response, one physician noted that "the importance of informed consent to risk
management lies in the contributions it makes to the doctor-patient relationship and overall
clinical care, much more so than in any future defense it may provide." Schouten, supra note
3, at 1360.
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of the reciprocal rights and duties that enable patients to trust their physi-
cians and participate in their own health care decisions.'"
The roots of informed consent in this country can be traced to a series of
opinions recognizing a patient's right to bodily autonomy.' 9 The frequently
quoted statement that "[e]very human being of adult years and sound mind
has a right to determine what shall be done with his own body" is an appeal-
ing endorsement of the right to self-determination.2 ° Yet, an analysis of
these early cases reveals the very limited nature of a patient's involvement in
his own health care. The evolution of informed consent began with a recog-
nition of the right to "simple consent," 21 exercised through a poorly defined
veto power over a proposed treatment.
In Mohr v. Williams,2 2 the patient submitted to an operation on her right
ear for the removal of a polyp. It was also suspected that the bones in the
middle ear were infected and should be removed as well.23 The patient
awoke from the operation to discover that the attending surgeon, with the
concurrence of the patient's family physician, had operated on the left ear
after determining that it was in greater need of care.24 While the facts of this
case and others like it25 are well known, the opinion of the Minnesota
Supreme Court established two points of departure for the nascent doctrine
of informed consent. First, the consent of the patient would be invoked only
18. Charles W. Lidz et al., Two Models of Implementing Informed Consent, 148
ARCHIVES INTERNAL MED. 1385, 1386 (1988).
19. Pratt v. Davis, 79 N.E. 562 (Ill. 1906); Mohr v. Williams, 104 N.W. 12 (Minn. 1905);
Schloendorff v. Society of N.Y. Hosp., 105 N.E. 92 (N.Y. 1914); Rolater v. Strain, 137 P. 96
(Okla. 1913); Hunter v. Burroughs, 96 S.E. 360 (Va. 1918).
20. See, e.g., Schloendorff, 105 N.E. at 93.
21. See PAUL S. APPELBAUM ET AL., INFORMED CONSENT: LEGAL THEORY AND
CLINICAL PRACTICE 38 (1987) (discussing the historical background of the legal requirements
for disclosure and consent).
22. 104 N.W. 12 (Minn. 1905).
23. Id. at 13.
24. Id.
25. There is an unfortunate legacy of outright deceit by physicians in obtaining consent to
treatment that far outstrips the well-intentioned actions of the doctor in Mohr. See Pratt v.
Davis, 79 N.E. 562 (Ill. 1906) (affirming judgment for patient when physician removed pa-
tient's uterus with full knowledge that no consent was obtained for the procedure); Bang v.
Charles T. Miller Hosp., 88 N.W.2d 186 (Minn. 1958) (questioning whether the patient was
informed that a bladder resection operation would lead to sterility); Corn v. French, 289 P.2d
173 (Nev. 1955) (leaving as a question of fact for the jury whether physician performed a
mastectomy when only given consent to perform a biopsy). One commentator noted that Bang
has been frequently used in informed consent litigation "because the injury suffered was not a
collateral hazard of the operation, but a part of the procedure to be accomplished." William
H. Karchmer, Informed Consent: A Plaintiff's Medical Malpractice "Wonder Drug," 31 Mo.
L. REV. 29, 38 (1966).
Informed Consent in Dermatology
when the physician's care involved surgery.2 6 Once the surgical remedy is
proposed, the patient decides "whether he will take his chances... of living
without [the operation]."" Second, the physician retains near absolute dis-
cretion as to the "methods of treatment."2  The Supreme Court of
Oklahoma elaborated on the second point in Rolater v. Strain.29 In an at-
tempt to distinguish Mohr, the defendant physician in Rolater contended
that "consent was given to an operation upon the [plaintiff's] right foot,
where it was performed."3° The court affirmed a judgment for the plaintiff
based on lack of consent because the nonremoval of any bones was an ex-
press condition of the operation, and "the patient had the right to insist upon
a strict performance" of the agreed parameters of consent.31
These early cases present a curious mixture of competing values at a time
when physician paternalism remained very entrenched.3 2 At the time, doc-
tors were allowed to effect their chosen treatments with little input from
their patients.33 In effect, the patient's right to redress under the law was
limited by the extent to which she was able to set the conditions of the doc-
tor's performance. However, the physician, because of his superior knowl-
edge, effectively controlled the parameters of the relationship.34
One precedent from this era "contained the seeds of the requirement of an
affirmative duty of disclosure.",35 In Hunter v. Burroughs, 36 the patient sub-
mitted to X-ray treatment to cure eczema, and this treatment damaged the
patient's skin. 37 The court upheld "the duty of a physician in the exercise of
ordinary care to warn a patient of the danger of possible bad consequences of
using a remedy" only in a very limited sense.3 ' Normally, the failure to
26. Mohr, 104 N.W. at 14; see also Pratt, 79 N.E. at 565; Rolater v. Strain, 137 P. 96, 97
(Okla. 1913).
27. Mohr, 104 N.W. at 15 (citation omitted).
28. Id. However, the court stated that the doctor did not have "free license respecting
surgical operations." Id.
29. 137 P. 96 (Okla. 1913).
30. Id. at 98. The procedure called for surgically draining an existing wound in the plain-
tiff's foot but resulted in the removal of the foot's sesamoid bone. Id. at 97.
31. Id. at 98.
32. For a discussion of medical paternalism as emanating from the Hippocratic tradition,
see JAMES F. CHILDRESS, WHO SHOULD DECIDE? PATERNALISM IN HEALTH CARE 39-43
(1982).
33. Id. at 7. The paternalistic doctor would view consent as acceptance of the proposed
treatment and refusal as an indication that the patient is incompetent. Id.
34. Marjorie M. Shultz, From Informed Consent to Patient Choice: A New Protected In-
terest, 95 YALE L.J. 219, 221 (1985).
35. APPELBAUM ET AL., supra note 21, at 38.
36. 96 S.E. 360, 361-62 (Va. 1918).
37. Id. at 362.
38. Id. at 366.
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warn was "not per se an act of negligence," but the physician in this case
"misled the plaintiff by not only not giving him the warning aforesaid, but by
affirmatively assuring him" that the X-ray treatment would be efficacious.39
An affirmative duty of disclosure was recognized in Salgo v. Leland Stan-
ford Jr. University Board of Trustees.' In this negligence action, the plaintiff
alleged that the doctor failed to competently perform a translumbar
aortography,4" which allegedly caused paralysis of the lower extremities.4 2
On appeal, the defendant physicians challenged a jury instruction mandating
that the duty of a physician is "to disclose to the patient 'all the facts which
mutually affect his rights and interests and of the surgical risk, hazard and
danger .... ' "" Finding that the instruction should be modified, the court
held that the physician rightfully retains a certain amount of discretion that
must be consistent with the full disclosure of facts necessary to an informed
consent." In "coin[ing] the term informed consent,"4 5 the court recognized
the physician's two alternative courses of action: disclosing every possible
risk to a patient or revealing the maximum amount needed before causing a
patient undue apprehension when there is, in fact, minimal risk involved.
4
Two courts had occasion to comment on this curious standard promul-
gated in Salgo.47 In Natanson v. Kline, the Supreme Court of Kansas found
that the Salgo rule provided a balance "between the two extremes of absolute
silence on the part of the physician relative to the treatment of a patient and
exhaustive discussion" of every conceivable danger of the treatment. 4 8 The
court provided some guidance in this area by stating that disclosure "is lim-
ited to those disclosures which a reasonable medical practitioner would
make under the same or similar circumstances., 49 The Supreme Court of
39. Id. 366-67.
40. 317 P.2d 170 (Cal. Dist. Ct. App. 1957).
41. Id. at 173. This procedure involves the injection of contrast dye material into the
patient's abdominal aorta and the taking of X-ray pictures of the area to locate any blockage of
blood flow. Id. at 174.
42. Id. at 175.
43. Id. at 181.
44. Id.
45. APPELBAUM ET AL., supra note 21, at 39.
46. Id. See generally Edmund Pellegrino, The Relationship of Autonomy and Integrity in
Medical Ethics, 24 BULL. PAN AM. HEALTH ORGANIZATION 361, 371 (1990) (finding that the
physician has a heightened responsibility to be sensitive to the vulnerable, frightened state of
the patient).
47. Natanson v. Kline, 350 P.2d 1093, 1095 (Kan. 1960) (involving a patient who suffered
excessive cobalt irradiation in the treatment of breast cancer); Mitchell v. Robinson, 334
S.W.2d 11, 18 (Mo. 1960) (involving induction of insulin shock and electroshock therapy caus-
ing unintended convulsions which resulted in several fractured vertebrae).
48. Natanson, 350 P.2d at 1104.
49. Id. at 1106.
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Missouri in Mitchell v. Robinson proposed that the duty to warn of hazards
and risks arose because the doctors knew of the high incidence of injury
associated with insulin shock therapy.5° In essence, Mitchell also endorsed
the emerging professional standard of disclosure approved of in Natanson by
recognizing that patient consent could be coupled with an understanding of
established medical practices.
This policy governing disclosure allowed the medical profession to set its
own standards for what was considered to be the appropriate disclosure of
information.5" As early as 1960, courts stated that a plaintiff's recovery de-
pended upon whether the physician's disclosure "squared with professional
custom." ' 52 In questioning this custom or professional standard of care, the
United States Court of Appeals for the District of Columbia Circuit noted in
Canterbury v. Spence" that "the reality of any discernible custom reflecting
a professional concensus [sic] on communication of option and risk informa-
tion to patients is open to serious doubt." '54 The Canterbury court further
reasoned that the duty to disclose arose "from phenomena apart from medi-
cal custom" and that the professional standard was "at odds with the pa-
tient's prerogative to decide on projected therapy himself."' 55 The court
ultimately held that all material risks must be disclosed to a patient prior to
50. 334 S.W.2d at 19.
51. Martin R. Studer, The Doctrine of Informed Consent: Protecting the Patient's Right to
Make Informed Health Care Decisions, 48 MONT. L. REV. 85, 90 (1987).
52. Id. at 89 (crediting Natanson v. Kline, 350 P.2d 1093 (Kan. 1960) with this new
theory of recovery for injured patients who can show neither negligent diagnosis nor treat-
ment). For an analysis of the present requirements of a cause of action based on the negligent
failure to obtain informed consent, see Richard E. Shugrue & Kathryn Linstromberg, The
Practitioner's Guide to Informed Consent, 24 CREIGHTON L. REV. 881 (1990-91). Informed
consent now forms the basis of two separate causes of action:
In a claim of battery... [i]t need only be shown that the medical procedure per-
formed was substantially different than that to which the patient consented. In negli-
gent nondisclosure cases... [t]he patient must prove that a reasonable person in the
patient's position would have refused the treatment had the physician disclosed the
risk.
Kohoutek v. Hafner, 383 N.W.2d 295, 299 (Minn. 1986).
53. 464 F.2d 772 (D.C. Cir. 1972).
54. Id. at 783 (footnote omitted). There are a number of factors which, in their totality,
cast doubt on the possibility of a uniform standard of practice, including "locality of the physi-
cian, availability of facilities, specialized or general practice, and proximity of specialists and
special facilities .... " Blair v. Eblen, 461 S.W.2d 370, 373 (Ky. Ct. App. 1970). These
various elements are presently subsumed in the debate over whether standards of care are
measured by local geography or by reliance on national standards. For medical specialists, the
majority of courts have imposed national standards of professional competence. See Jay M.
Zitter, Annotation, Standard of Care Owed to Patient by Medical Specialist as Determined by
Local, "Like Community," State, National, or Other Standards, 18 A.L.R.4TH 603, 608-20
(1982).
55. Canterbury, 464 F.2d at 786.
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consenting to surgery.56
Canterbury and its progeny reaffirmed that self-determination is the prin-
cipal goal of informed consent and that the patient's needs for information,
rather than the physician's practices, must form the basis of any adequate
standard of disclosure.7 However, use of the "reasonable person" to judge
the legitimacy of patient demands still compromises the amount of informa-
tion that may be given to individual patients.5" James Childress, known for
his autonomy-based ethics, suggests that "the rule of informed consent has
become too formalistic and that following it has become mechanical some-
times to the extent of violating its spirit."59 The following analysis attempts
to discover how these rules can positively guide medical practice, rather than
restrict it.
B. Improving Disclosure Practices
In classifying the duty to disclose standard as "the professional-ori-
ented"'  or the "patient-oriented ' 61 standard, one commentator has sug-
gested that both focuses should yield the same practical result. 62 However,
deficiencies in disclosure persist in daily practice, regardless of which legal
standard the physician feels obliged to follow. 63 Two areas of disclosure
warrant attention: the disclosure of treatment alternatives and the presenta-
56. Id. at 787. The court defined a risk as material "when a reasonable person, in what
the physician knows or should know to be the patient's position, would be likely to attach
significance to the risk or cluster of risks in deciding whether or not to forego the proposed
therapy." (quoting Jon R. Walz & Thomas W. Scheuneman, Informed Consent to Therapy, 64
Nw. U.L. REV. 628, 640 (1970)). See also Cobbs v. Grant, 502 P.2d 1, 11 (1972).
57. RUTH R. FADEN & TOM L. BEAUCHAMP, A HISTORY AND THEORY OF INFORMED
CONSENT 137 (1986).
58. Id.
59. See CHILDRESS, supra note 32, at 135.
60. Under this traditional approach, the physician must disclose to each patient as much
information as a reasonably prudent physician would disclose in the same situation. Marshall
B. Kapp, Informed Consent for Federal Clinicians, 154 MIL. MED. 238, 239 (1989); see also
supra note 34 and accompanying text.
61. This growing trend focuses on the materiality aspect of informed consent, questioning
how much information a patient would require to make an intelligent decision on a proposed
treatment that is consistent with personal values and preferences. Kapp, supra note 60, at 239;
see also supra note 46 and accompanying text.
62. Kapp, supra note 60, at 239.
63. Commentators note:
Many physicians feel the informed consent requirement imposes upon them an unde-
sirable and perhaps impossible task. It is considered undesirable because adequately
informing a patient takes too long and might create unnecessary anxiety. It is con-
sidered impossible because no medically uneducated and clinically inexperienced pa-
tient can truly grasp the significance of the information the physician must disclose.
ALBERT R. JONSEN ET AL., CLINICAL ETHICS: A PRACTICAL APPROACH TO ETHICAL DECI-
SIONS IN CLINICAL MEDICINE 64 (2d ed. 1986).
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tion of the possible risks and benefits of a procedure. 64
1. Treatment Alternatives
In an area of practice particularly important to this survey, the disclosure
of treatment alternatives is a necessary part of a patient's informed con-
sent.65 As noted above, informed consent developed from a milieu of physi-
cian paternalism. The patient would simply ratify or decline the doctor's
proposed treatment. However, the Natanson court gave official recognition
to the disclosure of treatment alternatives.66 While Natanson would not
properly stand as the progenitor of a new duty of disclosure, it recognized
that "[i]f the physician fails to disclose alternative forms of treatment, the
patient is precluded from expressing a preference among them."67
Essential to this analysis will be an understanding of what are considered
reasonable alternative procedures,68 which currently depend on the standard
adopted in the particular jurisdiction.69 Yet, it has been argued that some
congruence exists between the professional and reasonably prudent patient
standards. That is, physicians will be aware "that patients want to know
about more than what their physicians recommend" and recognize "that
greater disclosure is almost always preferable." 70
A review of cases and statutes referencing the duty to disclose alternate
treatments reveals that the determination of reasonibleness belies convenient
64. The practice of informed consent usually combines disclosure of all benefits as well as
all risks. See FAY A. RozovSKY, CONSENT TO TREATMENT: A PRACTICAL GUIDE 45 (2d ed.
1990). However, there are instances where benefits deserve separate treatment from that of
risks, particularly when the procedure is diagnostic rather than therapeutic or otherwise pro-
vides something less than full relief of the patient's suffering. See APPELBAUM ET AL., supra
note 21, at 55.
65. APPELBAUM ET AL., supra note 21, at 54.
66. Natanson v. Kline, 350 P.2d 1093, 1106 (Kan. 1960).
The term alternatives suggests that the physician has already determined what is best
for the patient, and that any other procedures are secondary in value .... Physicians
ought to suggest what they deem to be the medically preferable course. However, if
decision making about care were simply a matter of what is preferable on medical
grounds alone, there would be no need for the informed consent doctrine; simple
consent would do just as well if not better.
APPELBAUM ET AL., supra note 21, at 54.
67. JONSEN ET AL., supra note 63, at 68.
68. RoZOVSKY, supra note 64, at 50. In an early discussion of what is reasonableness, one
author advocated a "middle course" between wanton experimentation and a failure to keep up
with widely accepted medical advances. Angela R. Holder, Alternative Medical Procedures,
212 JAMA 385, 386 (1970).
69. See Hunter L. Prillaman, A Physician's Duty to Inform of Newly Developed Therapy, 6
J. CONTEMP. HEALTH L. & POL'y 43, 48 (1990).
70. Nancy M.D. King & Gail Henderson, Treatments of Last Resort: Informed Consent
and the Diffusion of New Technology, 42 MERCER L. REV. 1007, 1041 (1991).
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application of either standard of disclosure.71 In applying Utah law, a fed-
eral district court held that the state's standard of disclosure must be judged
by materiality and concluded that the disclosure of material information
included "any alternative treatments and the risk of no treatment at all.""
A similarly vague standard was adopted in the Indiana informed consent
statute which speaks only of the "reasonable" alternatives to a proposed
treatment.7 3
In Florida, a more specific standard has focused on what is considered to
be a medically "viable" or "accepted" alternative. 74 The statutory definition
approves of those alternatives "generally considered by the medical profes-
sion to be within the scope of current, accepted standards' 75 and inherently
adopts a professional standard of practice to determine if the treatment op-
tion should be disclosed. 7' This approach was also employed in Logan v.
Greenwich Hospital Ass'n, which considered whether a treatment alternative
that was more risky than the chosen method was in fact a viable alterna-
tive.77 The court held that to exclude the more difficult option would vitiate
any meaningful communication with a patient by automatically recom-
mending the "safest procedure.",78
For the practice of dermatology, advances in treatment are being made in
laser therapy and skin cancer management at a startling rate. The survey
responses indicate an overall willingness to refer patients with difficult
problems to modern facilities instead of effecting treatment with traditional
methods. 79 Standards similar to that promulgated in Logan have been criti-
71. This determination is made with the goal of discerning trends in clinical practice
which are defined by the law rather than of evaluating the requirements for maintaining a
negligent informed consent cause of action.
72. Unthank v. United States, 732 F.2d 1517, 1521 (10th Cir. 1984) (seeking recovery for
injuries sustained from swine flu inoculation).
73. IND. CODE ANN. § 16-9.5-1-4.(c)(5) (Bums 1990).
74. See FLA. STAT. ANN. § 458.324 (West 1991).
75. Id. § 458.324(1). The Florida statute specifically considers informed consent with re-
gard to the treatment of breast cancer. Compare ME. REV. STAT. ANN. tit. 24, § 2905-A
(West 1991) (requiring disclosure of "alternative efficacious methods of treatment of breast
cancer, including surgical, radiological or chemotherapeutic treatment or any other generally
accepted medical treatment"); PA. STAT. ANN. tit. 35, § 5641 (1991) (requiring patient to
attest that "I have been informed of the currently medically accepted alternatives to radical
mastectomy."). For a history of the development of modern treatments for this condition and
their impact on the informed consent process, see KATZ, supra note 8, at 175-84.
76. Prillaman, supra note 69, at 48 (stating that the determination of whether other prac-
titioners in the relevant community would have disclosed the alternative is made by comparing
the testimony of competing medical experts).
77. 465 A.2d 294, 301 (Conn. 1983).
78. Id.
79. See Tables 1-4.
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cized for not guiding physicians in the course of disclosure."s However, the
apparent tendency of courts to adopt a professional standard of disclosure
protects physicians from "having to describe the theories of quacks or to
explain treatments too new to have a track record," while retaining the
"duty to keep up with the relevant literature and other sources of informa-
tion, and to inform patients of new treatments as they meet the criteria of
acceptance."8 1
2. Risk-Benefit Information
One difficulty with requiring physicians to thoroughly disclose both the
risks and benefits of treatment alternatives is that the language used in char-
acterizing these alternatives "may not be solely descriptive" and may convey
the physician's "own positive or negative evaluation of various alterna-
tives."8 2 In the disclosure of benefits, the "greatest risk lies in the impulse to
improve the patient's morale by exaggerating the potential for benefits."8 s3
There is the added risk that by failing to detail fully the expected benefits of
a procedure the patient would be unable to adequately weigh the advantages
of choosing a particular treatment. For example, management of recurrent
basal cell carcinoma can be achieved by radiation therapy or Mohs micro-
graphic surgery. The advantages and disadvantages for each procedure
could be determinative for different patients, depending on their concerns
about cosmetic ramifications and long-term treatment goals.84
Case law and statutes are virtually silent on the issue of disclosing poten-
tial treatment benefits.8 5 The Hawaii informed consent statute does make
reference to the "anticipated results" of treatment as one criteria of complete
disclosure.6 Most patients would equate this standard, or the "purpose of
the procedure," with its "anticipated benefits."8 " Yet, even in a jurisdiction
80. ROZOVSKY, supra note 64, at 51.
81. Prillaman, supra note 69, at 58. The author describes official recognition as those
objective manifestations of approval by such institutional bodies as the Food and Drug Admin-
istration and the American Medical Association. Id. at 52-57. The use of the professional
standard of disclosure in this case is not at odds with the general theme of promoting the
patient's autonomy because the profession of dermatology has the ability to establish good care
practices which reflect the emerging technologies.
82. Daniel W. Brock, The Ideal of Shared Decision Making Between Physicians and Pa-
tients, 1 KENNEDY INST. ETHICS J. 28, 40 (1991).
83. Eric A. Plaut, The Ethics of Informed Consent: An Overview, 14 PSYCHIATRIC J. U.
OTTAWA 435, 436 (1989).
84. See infra note 108 and accompanying text.
85. APPELBAUM ET AL., supra note 21, at 55.
86. HAW. REV. STAT. § 671-3 (1985).
87. APPELBAUM ET AL., supra note 21, at 55. See, e.g., Gray v. Grunnagle, 223 A.2d 663,
674 (Pa. 1966) (requiring "understanding of the nature of the operation to be performed, the
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lacking a positive duty to disclose benefits information,88 such information
should be disclosed in an effort to engage the patient in the therapeutic
process.
While the physician should make recommendations as to the course of
treatment, the ability of patients to make informed choices is enhanced if
they are also appraised of the potential risks associated with each proce-
dure. 9 Realistically, all risks and options simply cannot be discussed.
Should the remote possibility of a needle breaking off in a vein or the rare
possibility of sepsis be discussed before every blood sample is ordered? To
address these concerns, four considerations have been proposed as a guide
for physicians trying to determine if disclosure is warranted: 1) the nature of
the risk; 2) the magnitude of the risk; 3) the probability that the risk might
materialize; and 4) the imminence of risk materialization.' In addition to
these guidelines, the law in each jurisdiction determines precisely how much
disclosure is required.91
Disclosure of risk-benefit information ranked well for each case presenta-
tion surveyed.92 However, further study will be needed to determine the
actual content of that disclosure.
V. CASE PRESENTATIONS
The results of this study suggest that disclosure practices differ widely,
perhaps inappropriately, with regard to the four case presentations in the
survey questionnaires. At a minimum, informed consent requires disclosure
and an understanding on the part of the patient of the significant alternative
diagnostic and treatment options and the potential risks and benefits of each
option. This information should also include the natural history of the dis-
ease if it remains untreated. In evaluating the responses below, practitioners
are admonished to determine the specific details of disclosure on an individ-
ual patient basis because a particular patient may have greater susceptibility
seriousness of it, the organs of the body involved, the disease or incapacity sought to be cured,
and the possible results.") (footnote omitted).
88. See GA. CODE ANN. § 31-9-6(d) (Michie 1991) (requiring disclosure in general terms
the treatment in connection with which consent is given).
89. A national survey of patient injury claims against dermatology residency programs
revealed that 50% of these claims "related to therapeutic or surgical complications." Eric S.
Hollabaugh et al., Patient Personal Injury Litigation Against Dermatology Residency Programs
in the United States, 1964-1988: Implications for Future Risk-Management Programs in Der-
matology and Dermatologic Surgery, 126 ARCHVvES DERMATOLOGY 618, 618 (1990).
90. APPELBAUM ET AL., supra note 21, at 51.
91. For an excellent survey of the law in each state, whether adopted by statute of judicial
opinion, see ROZOVSKY, supra note 64.
92. See Tables 1-4.
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to more serious complications or have an increased likelihood of injury from
complications due to the presence of predisposing risk factors.
A. Dysplastic Nevus Syndrome
93
Although controversy exists regarding the diagnosis and management of
the dysplastic nevus syndrome, this survey revealed a consensus regarding
some diagnostic and management tools for the specific case presentation.
One hundred percent of the respondents indicated they would disclose the
options of routine physician follow-up examinations, sun avoidance, and use
of sun protection strategies. The vast majority of respondents would disclose
routine self-examination of the skin (97.9%), surgical removal of selected
pigmented lesions (95.8%), and explain the familial component of the syn-
drome so that blood relatives could be examined (91.7%). Less than one-
half of the respondents would discuss other patient management options
such as the surgical removal of all pigmented lesions (20.8%), patient refer-
ral to a specialized pigmented lesion clinic for further evaluation and treat-
ment (33.3%), genetic counseling (39.6%), or limited photography for
suspicious lesions (41.7%).
The clinical option for excising all lesions in the dysplastic nevus syn-
drome is recognized. 94 This surgery may meet the legitimate needs of cer-
tain patients. For example, a person with the dysplastic nevus syndrome
and a strong family history of malignant melanoma who is working in an
area of the world without available medical care might well consider this
option." Although the excision of all nevi is rarely recommended by derma-
tologists as the best management choice for patients with the dysplastic ne-
93. The connection between dysplastic nevus syndrome (DNS) and malignant melanoma
is very important for the purposes of this survey. Dysplastic nevi (DN) are different from
other nevi (moles) in that they are typically larger, manifest a variety of colors, and have
irregular borders. THOMAS P. HABIF, CLINICAL DERMATOLOGY: A COLOR GUIDE TO
DIAGNOSIS AND THERAPY 561 (2d ed. 1990). The familial presentation of DNS has been
demonstrated to be a significant marker for the development of malignant melanoma, an
extremely dangerous tumor with "the ability to metastasize to any organ, including the brain
and heart." Id. at 564. Current research supports the view that DNS may also be associated
with increased melanoma risk outside the context of a family history of melanoma. Allan C.
Halpern et al., Dysplastic Nevi as Risk Markers of Sporadic (Nonfamilial) Melanoma, 127
ARCHIVES DERMATOLOGY 995, 999 (1991).
94. Eric S. Hollabaugh et al., supra note 89, at 621 (indicating that the least invasive
management option is a routine skin examination).
95. Removal of all nevi may lead to a false sense of security, causing the patient to forgo
periodic medical examination. David L. Shriner et al., Techniques of Full-Scale Colour Total
Body Photography: A Useful Tool in the Management of Patients with the Dysplastic Nevus
Syndrome, I J. DERMATOLOGICAL TREATMENT 181, 184 (1990). The false sense of security is
potentially deadly for the patient who no longer finds it necessary to examine his skin for
problematic lesions. Telephone Interview with Dr. Margaret Tucker, Director of Family
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vis syndrome,9 6 if the option is not disclosed, it cannot be selected.
Due to the apparent genetic component9 7 in this case presentation, genetic
counseling may allow the patient to exercise a choice in fathering a child
who could also inherit the dysplastic nevus syndrome. Failure to warn this
patient of the genetic component of his medical condition may lead to later
allegations of wrongful birth9" if his child develops the dysplastic nevus syn-
drome. However, most patients do not desire genetic counseling and view
the dysplastic nevus syndrome as a manageable condition. Because negli-
gent genetic counseling99 is the focus of much attention in the legal commu-
nity and the potential for costly litigation is high, it would seem prudent to
inform the patient of the possibility of transmitting the disease to any off-
spring and offer the option of genetic counseling.
Of the dermatologists surveyed, 60.4% would disclose this patient's risk
of death from malignant melanoma regardless of which patient management
strategy was employed. Discussion of the risk of death in most instances
helps the patient to understand the nature of the condition and choose realis-
tic management options. The early detection and treatment of malignant
melanoma is strongly predictive of a good prognosis.
Many of the respondents would disclose the option of an eye examination
(60.4%). In fact, it has been recommended that all patients with dysplastic
nevus syndrome and their families should be evaluated ophthalmologically
because of the possible association with ocular melanoma." One
Studies Section, Environmental Epidemiology Branch, National Cancer Institute (Jan. 2,
1992) [hereinafter Tucker Interview].
96. See RONA M. MACKIE, SKIN CANCER: AN ILLUSTRATED GUIDE TO THE AETI-
OLOGY, CLINICAL FEATURES, PATHOLOGY AND MANAGEMENT OF BENIGN AND MALIG-
NANT CUTANEOUS TUMOURS 177 (1989).
97. In the DNS-familial case presentation there is a high risk of dying from melanoma
unless changing lesions (Le., those which turn dark, become scaly in texture, or irregular in
size) are removed and the patient is educated about recognizing melanoma through regular
self-examination and warned to avoid exposure to the sun. Id.
98. See, e.g., Gallagher v. Duke Univ., 852 F.2d 773 (4th Cir. 1988) (action against
cytogeneticist after second child was born with severe physical and mental defects); Viccaro v.
Milunsky, 551 N.E.2d 8 (Mass. 1990) (action against physician after second child was born
with anhidrotic ectodermal dysplasia); Azzolino v. Dingfelder, 337 S.E.2d 528 (N.C. 1985)
(action against health service, doctor, and nurse when child was born with Down's Syndrome).
99. The low response rate for genetic counseling in the survey may be attributable to the
fact that it would take about two hours for a practitioner to effectively counsel this patient.
Therefore, referral to a genetics clinic may be more efficient. Tucker Interview, supra note 95.
See also Robin J. Caldwell & Walter E. Nance, Genetic Counseling for Problems Affecting
Older Children and Adults, in COUNSELING IN GENETICS 121, 121-22 (Y. Edward Hsia et al.
eds., 1979).
100. Rene S. Rodriguez-Sains, Ocular Findings in Patients with Dysplastic Nevus Syndrome,
93 OPHTHALMOLOGY 661, 661 (1986) ("Dysplastic nevus syndrome patients may acquire me-
lanomas at an earlier age than the general population, and have multiple cutaneous melanomas
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ophthamologist reported that there are no instances of a patient having both
primary ocular and cutaneous malignant melanoma absent the dysplastic
nevus syndrome. 1O
Limited photography for isolated suspicious lesions is difficult to support
because any lesion initially suspected as malignant melanoma should be
managed by biopsy,'0 2 not photography. There is significant medicolegal
risk for the clinician who photographs an isolated suspicious pigmented le-
sion only to later discover that it is a malignant melanoma. Regional pho-
tography is a useful type of limited photography when most of the dysplastic
nevi are located in one area, such as the back. In this situation, photograph-
ing the back only will be less expensive for the patient and will also serve as
an objective standard during future examinations of the back lesions. The
reason for obtaining complete photodocumentation in the dysplastic nevus
syndrome is to provide a baseline for later objective comparison. 3
Over 70% of the respondents would discuss the option of obtaining
photodocumentation of all of the lesions. This approach is useful as a
clinical tool for physicians attempting to diagnose early malignant mela-
noma in patients with the dysplastic nevus syndrome."° The photodocu-
mentation of high risk patients under surveillance for malignant melanoma
led to the detection of 23.1% new tumors.105 As more evidence mounts in
support of photodocumentation, it is likely that more dermatologists will
disclose this option.
B. Recurrent Basal Cell Carcinoma'0°
In the recurrent basal cell carcinoma case presentation, 97.9% of the re-
as well as other multiple primary malignancies, including a possible association with ocular
melanomas.") (footnotes omitted).
101. Rene S. Rodriguez-Sains, Ocular Melanomas, 3 DERMATOLOGIC CLINICS 297, 305
(1985).
102. See generally Michael A. Goldenhersh, Indications for Skin Biopsy: Ethical Considera-
tions, 8 AM. J. DERMATOPATHOLOGY 265 (1986) (presenting numerous reasons why derma-
tologists should and should not obtain skin biopsies); Randall K. Roenigk, Excision, in
DERMATOLOGIC SURGERY: PRINCIPLES AND PRACTICE 155 (Randall K. Roenigk & Henry
H. Roenigk, Jr. eds., 1989) (listing indications where an excisional biopsy would provide defin-
itive information).
103. See Shriner et al., supra note 95, at 184.
104. Jason K. Rivers et al., Clinical Characteristics of Malignant Melanomas Developing in
Persons With Dysplastic Nevi, 65 CANCER 1232, 1235 (1990).
105. See Gayle D. Marsi et al., Screening and Surveillance of Patients at High Risk for
Malignant Melanoma Result in Detection of Earlier Disease, 22 J. AM. ACAD. DERMATOLOGY
1042, 1046 (1990).
106. This malignant epithelial tumor of the skin arises from basal cells of the epidermis and
its appendages but rarely metastasizes. G. W. Milton & Anne O'Neill, Tumours of the Skin, in
SURGICAL MANAGEMENT 977, 978 (Niall J. O'Higgins et al. eds., 2d ed. 1991).
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spondents would disclose the option of Mohs micrographic surgery while
only 16.7% would disclose the option of treatment by radiation therapy.
10 7
This finding is surprising given the wide availability and historic use of radi-
ation therapy for skin cancer. Although Mohs micrographic surgery enjoys
a statistically superior cure rate for recurrent basal cell carcinoma when
compared to radiation therapy, 10 8 the ultimate decision regarding the choice
of treatment must rest with the patient. Therefore, the option of radiation
therapy should be explained to the patient along with its advantages and
disadvantages." °9 Similarly, the advantages and disadvantages of other
treatment options such as cryotherapy," curettage,'" and electrosur-
gery" 2 should be disclosed, even if they are not recommended.
C. Malignant Melanoma
In the case presentation of malignant melanoma, only 52.1% of the re-
spondents would discuss an elective lymph node dissection. Controversy ex-
ists in the medical literature regarding whether an elective lymph mode
dissection will benefit the type of patient described in the case.1 3 The deci-
107. For a comparison of cure and recurrence rates for basal cell carcinoma by radiation
therapy, see Perry Robins & Bias A. Reyes, Cure Rates of Skin Cancer Treated by Mohs Micro-
graphic Surgery, in DERMATOLOGIC SURGERY: PRINCIPLES AND PRACTICE 853, 855 (Randall
K. Roenigk & Henry H. Roenigk, Jr. eds., 1989). It is encouraging to the profession that
dermatologists who do not practice Mohs surgery will refer patients for this therapy when they
could perform treatment with less effective (and fee generating) methods.
108. Dan E. Rowe et al., Mohs Surgery Is the Treatment of Choice for Recurrent (Previously
Treated) Basal Cell Carcinoma, 15 J. DERMATOLOGIC SURGERY & ONCOLOGY 424, 424
(1989).
109. One advantage is that there are no surgical risks involved and, therefore, no cosmetic
reconstruction is needed. Disadvantages include a lower cure rate than Mohs micrographic
surgery, the necessity for frequent radiation treatments, local and regional side effects, future
management problems should radiation fail, and increased risk of a second primary tumor in
the radiation portal.
110. Cryotherapy destroys cutaneous lesions by freezing with liquid nitrogen. The amount
of freezing time will depend on the size of the lesion. Zachary, supra note 12, at 67. For a
discussion of possible complications associated with this procedure, see Setrag A. Zacarian,
Complications, Indications, and Contraindications in Cryosurgery, in CRYOSURGERY FOR SKIN
CANCER AND CUTANEOUS DISORDERS 283 (Setrag A. Zacarian ed., 1985).
111. Curettage involves the use of a curette, a sharp round instrument, which scoops the
lesion in one movement of the hand, while the skin is stabilized with the other hand. Roy C.
Grekin, Physical Modalities of Dermatologic Therapy, in ANDREWS' DISEASES OF THE SKIN:
CLINICAL DERMATOLOGY 1008, 1009 (Harry L. Arnold et al. eds., 1990).
112. Destruction of tumor tissue is achieved by an electrical current. There are two types
of electrosurgery: electrofulguration and electrodesiccation. In electrofulgration, an electric
arc applied to the carcinoma "induces a superficial injury with charring, relatively fast healing,
and low scar formation potential." Zachary, supra note 12, at 67. In electrodesiccation, a
treatment electrode must contact the skin. Id. The latter type of electrosurgery is associated
with a deeper tissue injury. Id.
113. HABIF, supra note 93, at 579. The determination to employ this surgical operation is
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sion of many respondents not to discuss elective lymph node dissection with
this patient may be related to the selected management option of referring
the patient to another physician for additional surgery." 4 Nonetheless, the
survey shows that dermatologists are likely to discuss a regional lymph node
dissection as an option in this setting."' Similarly, 56.3% of the respon-
dents would disclose the option of a medical oncology consultation to the
patient which otherwise may be left to the physician performing the defini-
tive surgery.
A small minority of the respondents would disclose experimental options
for the management of this malignant melanoma such as hyperthermia
(6.3%) and immunotherapy (4.2%).' 16 However, liability for failure to dis-
close experimental options is unusual." 7
D. Neonatal Port- Wine Stain
With respect to the newborn girl who has a neonatal port-wine stain,"'
70.8% of the respondents would discuss with the parents the option of eval-
made by estimating whether metastasis has occurred into a nearby lymph node drainage path-
way. Id. One study has shown that 28% to 38% of patients with stage I melanoma of greater
than .76 mm thick had prophylactic or elective lymph node dissections. See Yeu-Tsum Lee,
Loco-Regional Primary and Recurrent Melanoma: III. Update of Natural History and Non-
Systemic Treatments, (1980-1987), 15 CANCER TREATMENT REVIEWS 135, 140-41 (1988).
114. This re-excision surgery assumes that the lesion has been biopsied to determine the
presence of melanoma before subjecting the patient to further surgery. Patricia A. Ledwig &
June K. Robinson, Should the Excisional Biopsy of Clinically Probable Melanomas Include a
Margin that Might Also Serve as Adequate for Treatment?, 126 ARCHIVES DERMATOLOGY
877, 878 (1990).
115. Darrell S. Rigel & Robert J. Friedman, Benign and Malignant Tumors of Pigment-
Producing Cells, in PRINCIPLES AND PRACTICE OF DERMATOLOGY 225, 245 (W. Mitchell
Sams & Peter J. Lynch eds., 1990).
116. For a discussion of the latest developments in marshalling the body's immune system
to fight cancerous cells, see Robin Herman, The New Weapons, WASH. POST, Dec. 3, 1991,
Health Magazine, at 14. To date, it is unclear whether the therapeutic elevation of body tem-
perature or hyperthermia is clinically efficacious in the treatment of melanoma.
117. See King & Henderson, supra note 70, at 1029-38. For a comparison of the role of
informed consent in the experimental trial, see Paul Ramsey, The Patient as Person-Explora-
tions in Medical Ethics, in EXPERIMENTATION WITH HUMAN BEINGS 589 (Jay Katz ed.,
1972).
118. Both the neonatal port-wine stain and the Sturge-Weber syndrome are characterized
by capillary hemangiomas. The skin discoloration associated with these cases usually occurs
on the face and head. Specifically, the port-wine stain usually "involves the face in the distri-
bution of the sensory branches of the fifth cranial nerve." R. F. Stevenson et al., Unrecognized
Ocular Problems Associated with Port- Wine Stain of the Face in Children, 111 CANADIAN
MED. ASS'N J. 953, 953 (1974). The Sturge-Weber syndrome typically follows the first branch
of the trigeminal nerve. John Y.M. Koo, Neurocutaneous Disorders, in PRINCIPLES AND
PRACTICE OF DERMATOLOGY 867, 873 (W. Mitchell Sams & Peter J. Lynch eds., 1990).
Some patients with port-wine stains will also have Sturge-Weber Syndrome.
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uation for possible treatment by a pulsed dye laser.119 Fewer respondents
would discuss treatment with the argon laser12 (25%) or the carbon dioxide
laser (4.2%) despite the plea by one physician to let the patient decide about
the acceptable risks and benefits of using these two methods for treating a
port-wine stain.
121
Of the dermatologists surveyed, 72.9% would discuss getting an eye eval-
uation and a neurology consultation. Since glaucoma and seizures are asso-
ciated with the Sturge-Weber syndrome,'22 evaluation along these lines is
prudent. If glaucoma is discovered, intervention might prevent loss of vi-
sion. "' One physician recommends that patients having a port-wine cover-
ing the entire cranial nerve VI distribution associated with V2 involvement
should receive serial ophthalmologic examinations. 24 Other ophthalmolo-
gists have suggested that all patients with any type of facial port-wine stain
should have routine eye examinations because of the risk of glaucoma. 125
Early neurologic evaluation may be able to discern which infants with port-
wine stains are at risk for subsequent neurological complications.
VI. CONCLUSION
This study has endeavored to show that the goal of preserving patient
autonomy in the context of informed consent does not diminish the efficacy
of the therapeutic process. 126 The physician must be prepared to disclose
significant alternative treatment options to the patient and provide the
amount of information necessary to the patient's understanding of the poten-
tial risks and benefits of each option. On the basis of this survey, dermatolo-
gists should be concerned on two levels. First, a review of disclosure
practices should be undertaken to determine whether they satisfy the legal
requirements of their particular jurisdiction. Second, the legal requirements
for disclosure should not serve as the outer limit of acceptable disclosure
119. The pulsed dye laser is regarded as the best treatment tool for the port-wine stain with
the advantages of high response rates, slight damage to surrounding healthy tissue, little or no
pain during the procedure, and a small risk of scarring. Grekin, supra note 11, at 1015.
120. There is a high risk of scarring associated with using an argon laser on the port-wine
stain. Id. at 1014.
121. See R. Rox Anderson, Carbon Dioxide Lasers: A Broader Perspective, 123 ARCHIVES
DERMATOLOGY 566, 567 (1987).
122. See Amy S. Paller, The Sturge- Weber Syndrome, 4 PEDIATRIC DERMATOLOGY 300,
301 (1987).
123. See id. at 303.
124. Id.
125. Stevenson et al., supra note 118, at 954.
126. There is the added goal of providing some guidance of what physicians might rou-
tinely tell their patients in day-to-day practice, and it is hoped that this survey may help begin
to address the perceived lack of study in this area.
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practices. That is, dermatologists should endeavor to recognize those areas
where the profession can promote more efficacious treatment.
Contrary to those who propose that informed consent cannot accommo-
date the perceived competing values of autonomy and physicians' delivery of
health care services,' 27 this survey has shown that these values can be com-
plementary. If advances in dermatological medicine and surgery are to con-
tinue, doctors must avoid the tendency of focusing on the "institutional rules
of informed consent" to the exclusion of developing a conscientious under-
standing of an individual patient's needs.
127. See E. Silverman, The Myth of Informed Consent: In Daily Practice and in Clinical
Trials, 15 J. MED. ETHicS, Mar. 1989, at 7, 10.
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FIGURE I
Options
Disclosed
Mean (X) and standard deviation (SD) for the number of options
disclosed for case presentations of dysplastic nevus syndrome, recurrent
basal cell carcinoma, malignant melanoma and neonatal port-wine stain.
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TABLE 1 - DYSPLASTIC NEVUS SYNDROME
Case 1
A 34 year-old man presents to your office with several hundred unusual
pigmented lesions scattered over his body. Most lesions are on sun-exposed
areas. He relates to you that his mother, father, sister, and paternal
grandfather died of malignant melanoma.
You decide to sample several of the nevi and the pathology report shows
"moderate to severe dysplastic pattern." You diagnose dysplastic nevus
syndrome, familial type.
Please circle all the patient management options that you would discuss with
this patient. Choose as many as apply to this case.
Survey Responses
% number
100 48 routine physician follow-up examinations
100 48 sun avoidance and use of sun protection strategies
97.9 47 routine self-examination of the skin
95.8 46 surgical removal of selected pigmented lesions
91.7 44 follow-up of blood relatives
83.3 40 natural history of disease if no medical intervention
79.2 38 risks and benefits of various patient management
strategies
70.8 34 total-body photographs
60.4 29 eye examination
60.4 29 risk of patient death from malignant melanoma
41.7 20 limited photography
39.6 19 genetic counseling
33.3 16 pigmented lesion clinic
20.8 10 surgical removal of all pigmented lesions
2.1 1 video computer imaging digital photography
2.1 1 refer to university
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TABLE 2 - RECURRENT BASAL CELL CARCINOMA
Case 2
A 45 year-old woman presents to you with a red sclerotic 0.8 x 0.9 cm
plaque on the right ala. Three years ago she had a primary basal cell
carcinoma at the same location treated by cryosurgery. Your biopsy shows a
basal cell carcinoma. You diagnose a recurrent basal cell carcinoma.
Please circle all the patient management options that you would discuss with
this patient. Choose as many as apply to this case.
Survey Responses
% number
97.9 47 Mohs micrographic surgery
70.8 34 natural history of disease if no medical intervention
70.8 34 risks and benefits of various patient management
strategies
52.1 25 routine follow-up
31.3 15 local (conventional) excision of the lesion yourself
25 12 local (conventional) excision by other surgeon
22.9 11 local (conventional) excision by another dermatologic
surgeon
16.7 8 radiation therapy
14.6 7 curettage and electrosurgery
10.4 5 cryotherapy
2.1 1 plastic surgery consult
2.1 1 refer to university
2.1 1 excision with frozen section control
Informed Consent in Dermatology
TABLE 3 - MALIGNANT MELANOMA
Case 3
A 25 year-old man presents to you with a 0.5 x 0.7 cm diameter pigmented
nodule on the right anterior thigh. Your excisional biopsy with 0.30 cm
margins shows a malignant melanoma, 2.5 mm thick. There are no clinical
lymph nodes present and metastatic evaluation is otherwise negative.
Please circle all the patient management options that you would discuss with
this patient. Choose as many as apply to this case.
Survey Responses
% number
75 36 re-excision by another surgeon
64.6 31 risks and benefits of various patient management
strategies
62.5 30 natural history of disease if no medical intervention
56.3 27 medical oncology consultation
52.1 25 elective lymph node dissection
41.7 20 surgical oncology consultation
25 12 re-excising the lesion yourself
18.8 9 re-excision by another dermatologic surgeon
12.5 6 limb perfusion
8.3 4 immunology consultation
6.3 3 hyperthermia
4.2 2 immunotherapy
2.1 1 periodic dermatologic follow-up exams
2.1 1 refer to university because of potential medicolegal
liability
2.1 1 total skin exam, remove suspicious nevi, obtain family
history, routine follow-up
2.1 1 pigmented lesion conference with panel of specialists
2.1 1 refer to another institution
1992]
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TABLE 4 - NEONATAL PORT-WINE STAIN
You are called to the hospital to consult on a newborn girl who has a large
macular port-wine stain involving the right forehead, upper and lower
eyelids, cheek and nose.
Please circle all the patient management options that you would discuss with
this patient's parents. Choose as many as apply to this case.
Survey Responses
% number
77.1 37 risks and benefits of various patient management
strategies
75 36 management of port-wine stain with make-up
72.9 35 eye evaluation
72.9 35 neurology consultation
70.8 34 evaluation and possible treatment with pulsed dye laser
54.2 26 port-wine stain enlarging and darkening over time
43.8 21 port-wine stain fading over time
25 12 evaluation and possible treatment with argon laser
8.3 4 refer to another institution
4.2 2 evaluation and possible treatment with carbon dioxide
laser
4.2 2 evaluation and possible treatment with steroid injections
2.1 1 evaluation and possible treatment with skin grafting
2.1 1 evaluation and possible treatment with a laser in future
2.1 1 late onset capillary hemangioma nodules within lesion
